Summary
None of the AI statements provided relate to FDA-approved prescribing information for NORPRAMIN (indications, dosing, contraindications, boxed warnings, warnings/precautions, interactions, populations, adverse reactions). The label excerpts focus on clinical safety/efficacy, not cost/insurance/pharmacy pricing.
Category Scores
Accurate Statements
Unsupported Statements
Generic desipramine is usually less expensive than the brand.
Not supported by the provided FDA prescribing information excerpts (which contain no pricing, cost, insurance, formulary, or pharmacy markup statements).
Desipramine price varies by strength (mg).
Not supported by the provided FDA prescribing information excerpts.
Desipramine price varies by dosage form (tablet vs. liquid).
Not supported by the provided FDA prescribing information excerpts.
Desipramine price varies by whether it is brand or generic.
Not supported by the provided FDA prescribing information excerpts.
Desipramine price varies by pharmacy markup.
Not supported by the provided FDA prescribing information excerpts.
Desipramine price varies by insurance coverage.
Not supported by the provided FDA prescribing information excerpts.
Desipramine price varies by whether you are paying cash.
Not supported by the provided FDA prescribing information excerpts.
With insurance, out-of-pocket cost is often tied to formulary tier.
Not supported by the provided FDA prescribing information excerpts.
Generic tiers are usually cheaper.
Not supported by the provided FDA prescribing information excerpts.
With insurance, out-of-pocket cost depends on deductible status.
Not supported by the provided FDA prescribing information excerpts.
With insurance, out-of-pocket cost depends on whether the pharmacy is in-network vs. out-of-network.
Not supported by the provided FDA prescribing information excerpts.
With insurance, prior authorization may be required for desipramine.
Not supported by the provided FDA prescribing information excerpts.
Prior authorization is less common for generics but possible.
Not supported by the provided FDA prescribing information excerpts.
Switching to another desipramine formulation (same active ingredient) can sometimes reduce costs.
Not supported by the provided FDA prescribing information excerpts (and the excerpts provided do not discuss cost, formulary considerations, or formulation-switching for cost purposes).
Discussing alternative antidepressants with a clinician can sometimes reduce costs.
Not supported by the provided FDA prescribing information excerpts (which do not provide guidance on cost-driven switching or discuss cost outcomes).
Contradictions
Important Omissions
No FDA-label claims were addressed: e.g., indication, dosage/administration guidance, contraindications (MAOI timing and MI acute recovery), boxed warning content, warnings/precautions, drug interactions, adverse reactions, and pediatric use restrictions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided AI statements are about costs/insurance logistics and do not conflict with the boxed warning, contraindications, or other clinical safety content in the supplied label excerpts. However, they are not label-supported and therefore do not demonstrate adherence to FDA-approved prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims focus on pricing/insurance/prior authorization and cost-lowering strategies that are absent from the provided NORPRAMIN prescribing information excerpts.
Suggested Improvement
Limit statements to label-supported content (indication, dosing, contraindications, boxed warning/warnings, interactions, adverse reactions, and labeled population guidance). If discussing access or cost, qualify as non-label information and avoid implying FDA-label support.